EX-12.1

Exhibit 12.1

Regeneron Pharmaceuticals, Inc.
Computation of Ratio of Earnings to Combined Fixed Charges
(Dollars in thousands)



		2003			2004		2005			2006			2007

Earnings:
Income (loss) from continuing operations before income (loss) from equity investee	$	(107,395	)	$	41,565	$	(95,456	)	$	(103,150	)	$	(105,600	)
Fixed charges		14,108			14,060		13,687			13,643			13,708
Amortization of capitalized interest		33			78		78			73			23
Interest capitalized		(276	)		—		—			—			—


Adjusted earnings	$	(93,530	)	$	55,703	$	(81,691	)	$	(89,434	)	$	(91,869	)

Fixed charges:
Interest expense	$	11,932		$	12,175	$	12,046		$	12,043		$	12,043
Interest capitalized		276			—		—			—			—
Assumed interest component of rental charges		1,900			1,885		1,641			1,600			1,665


Total fixed charges	$	14,108		$	14,060	$	13,687		$	13,643		$	13,708


Ratio of earnings to fixed charges		(A	)		3.96		(A	)		(A	)		(A	)


(A)		Due to the registrant’s losses for the years ended December 31, 2003, 2005, 2006, and 2007 the ratio coverage was less than 1:1. To achieve a coverage ratio of 1:1, the registrant must generate additional earnings of the amounts shown in the table below.